In Depth 19 Jan 2024
Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?
Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.
In Depth
- Latest Posts
In Depth 18 Jan 2024
GLP-1 agonists: what’s the hype about?
GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.
In Depth 17 Jan 2024
Bladder cancer treatment: where are we standing?
Bladder cancer is the 10th most common cancer. Delve into the most promising strides in bladder cancer treatment.
In Depth 10 Jan 2024
The biggest private biotech investments in December 2023
The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players attracted the biggest funding rounds overall. Although December is generally a quiet time for biotech fundraising, there were still some big rounds raised in the […]
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
In Depth 11 Dec 2023
European patents in biotech: how to prevent invalid patents?
The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process is complex but essential. As […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 7 Dec 2023
The biggest private biotech investments in November 2023
The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
In Depth 27 Nov 2023
How are R&D Tax Incentives shaping Australia’s biotech future?
Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […]
In Depth 23 Nov 2023
The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy
Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]
In Depth 22 Nov 2023
Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment
Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]
In Depth 16 Nov 2023
uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?
Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA game? The Danish company, which […]
ADVERTISEMENT
